Search Result

Results for "

UGT1A1-IN-1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) Autophagy (1) Calcium Channel (1) COX (1) Cytochrome P450 (2) Endogenous Metabolite (1) Fc Receptor (FcR) (1) Fluorescent Dye (1) HBV (1) Interleukin Related (1) Keap1-Nrf2 (2) Leukotriene Receptor (1) NF-κB (1) NO Synthase (1) p38 MAPK (1) PGE synthase (1) Platelet-activating Factor Receptor (PAFR) (1) RANKL/RANK (1) Reactive Oxygen Species (ROS) (1) Reference Standards (1) TNF Receptor (1) UGT (4)
By Research Areas:	Cancer (1) Cardiovascular Disease (1) Infection (3) Inflammation/Immunology (2) Metabolic Disease (5) Neurological Disease (1)

By Targets:

Apoptosis (1)

Autophagy (1)

Calcium Channel (1)

COX (1)

Cytochrome P450 (2)

Endogenous Metabolite (1)

Fc Receptor (FcR) (1)

Fluorescent Dye (1)

HBV (1)

Interleukin Related (1)

Keap1-Nrf2 (2)

Leukotriene Receptor (1)

NF-κB (1)

NO Synthase (1)

p38 MAPK (1)

PGE synthase (1)

Platelet-activating Factor Receptor (PAFR) (1)

RANKL/RANK (1)

Reactive Oxygen Species (ROS) (1)

Reference Standards (1)

TNF Receptor (1)

UGT (4)

By Research Areas:

Cancer (1)

Cardiovascular Disease (1)

Infection (3)

Inflammation/Immunology (2)

Metabolic Disease (5)

Neurological Disease (1)

Inhibitors & Agonists

Natural
Products

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-111832

1,2,3,6-Tetragalloylglucose TeGG	UGT	Infection Metabolic Disease
1,2,3,6-Tetragalloylglucose (TEgG) is a competitive inhibitor of UDP-glucuronyltransferase *UGT1A1, targeting the competitive substrate binding site of UGT1A1. 1,2,3,6-Tetragalloylglucose inhibits UGT1A1-mediated β-estradiol 3-glucuronidation and SN-38 glucuronidation with IC₅₀* of 6.01 μM and 4.31 μM, respectively, and binds to UGT1A1 with K_i of 3.55 μM. 1,2,3,6-Tetragalloylglucose also induces tumor cell apoptosis, inhibit cell proliferation, activates caspase-3 and induces DNA fragmentation in HL-60 cells. 1,2,3,6-Tetragalloylglucose also inhibits HIV integrase and reverse transcriptase, and inhibits HCV protease .

HY-160250

*UGT1A1-IN-1*	Fluorescent Dye UGT	Metabolic Disease
UGT1A1-IN-1 is a *UGT1A1* inhibitor and fluorescent probe (Ex=370 nm, Em=520 nm), with an IC₅₀ of 1.33 μM and a K_i of 5.02 μM. UGT1A1-IN-1 is selectively glucuronidated by UGT1A1 at the bilirubin homologous binding site, and its PET effect is blocked along with this reaction, triggering fluorescence changes. UGT1A1-IN-1 can serve as a substitute for bilirubin to detect UGT1A1 activity and perform high-throughput screening of UGT1A1 modulators .

HY-N0762

Isobavachin 5 Publications Verification	Cytochrome P450 UGT p38 MAPK NF-κB NO Synthase COX Fc Receptor (FcR) RANKL/RANK Keap1-Nrf2 Reactive Oxygen Species (ROS) Apoptosis Autophagy	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Isobavachin is an orally active, blood-brain barrier-penetrating prenylated flavonoid present in Psoralea corylifolia. Isobavachin inhibits human CYP2B6, CYP2C9, CYP2C19, *UGT1A1, UGT1A9*, and UGT2B7. Isobavachin suppresses MAPK activation, NF-κB nuclear translocation, overexpression of iNOS/COX-2, FcεRI-mediated signaling pathways, and RANKL-induced osteoclastogenesis. Isobavachin induces autophagy, cytotoxicity, neuronal differentiation, and NRF2 activation; it alleviates oxidative damage, inflammatory responses, apoptosis, iron accumulation, mitochondrial biogenesis, and mast cell degranulation. Isobavachin is applicable to research related to liver injury, inflammatory diseases, osteoporosis, liver cancer, prostate cancer, glioma, periodontitis-induced bone loss, and Alzheimer's disease .

HY-N4267

Yangambin	Calcium Channel Platelet-activating Factor Receptor (PAFR) UGT Leukotriene Receptor TNF Receptor PGE synthase Interleukin Related	Cardiovascular Disease Infection Inflammation/Immunology
Yangambin is a PAF receptor antagonist and *UGT1A1/UGT1A3* inhibitor, with an IC₅₀ of 29.7 μM and a K_i of 17.1 μM against human *UGT1A1, and an IC₅₀* of 56.5 μM and a K_i of 66.8 μM against human UGT1A3. Yangambin blocks PAF-mediated responses, inhibits LTB₄-mediated neutrophil infiltration, and suppresses inflammatory events and anaphylactic contraction. Yangambin acts as a central nervous system inhibitor to reduce spontaneous activity, and also exhibits analgesic, anticonvulsant, antileishmanial, vasodilatory and hypotensive effects. Yangambin blocks voltage-gated Ca ²⁺ channels, reduces the production of NO, TNF-α, IL-6 and PGE2 in cells, increases the production of IL-10, and exerts a protective effect against cardiovascular injury. Yangambin can be used in research related to allergies, cutaneous leishmaniasis, central nervous system diseases and cardiovascular diseases .

HY-N1902R

4-Hydroxyphenylacetic acid (Standard)	Reference Standards Keap1-Nrf2 Endogenous Metabolite	Metabolic Disease
4-Hydroxyphenylacetic acid (Standard) is the analytical standard of 4-Hydroxyphenylacetic acid. This product is intended for research and analytical applications. 4-hydroxyphenylacetic acid, a major microbiota-derived metabolite of polyphenols, is involved in the antioxidative action. 4-hydroxyphenylacetic acid induces expression of Nrf2 . IC₅₀ & Target:Nrf2 In Vivo: 4-Hydroxyphenylacetic acid (6, 12, or 25 mg/kg) increases Nrf2 translocation to the nucleus and enhances the activity of phase II and antioxidant enzymes. The protein levels of nuclear Nrf2 are increased by 170% and 230% in pre-treated 12 and 25 mg/kg 4-Hydroxyphenylacetic acid groups, respectively, compared with the control group.The 4-Hydroxyphenylacetic acid pretreatment at a final dose of 25 mg/kg markedly and selectively up-regulated the target genes of phase II enzymes and resulted in higher up-regulation than that of the control group by 270%, 400%, and 500% or UGT1A1, UGT1A9, and SULT2A1, respectively. 4-Hydroxyphenylacetic acid also suppresses the expression of CYP2E1 .

HY-124364

RO6889678	HBV Cytochrome P450	Infection Metabolic Disease
RO6889678 is a highly potent HBV capsid formation inhibitor with a complex absorption, distribution, metabolism, and excretion (ADME) profile. RO6889678 is a potent inducer of CYP3A4 and coregulated proteins in human hepatocytes. RO6889678 is metabolized by a combination of CYP3A4-mediated oxidation and UDP-glucuronosyltransferase UGT1A3- and UGT1A1-mediated direct glucuronidation .

Cat. No.	상품명	Category	Target	Chemical Structure

HY-111832

1,2,3,6-Tetragalloylglucose TeGG	other families Classification of Application Fields Phenols Polyphenols Metabolic Disease Plants Disease Research Fields Source Classification	UGT
1,2,3,6-Tetragalloylglucose (TEgG) is a competitive inhibitor of UDP-glucuronyltransferase *UGT1A1, targeting the competitive substrate binding site of UGT1A1. 1,2,3,6-Tetragalloylglucose inhibits UGT1A1-mediated β-estradiol 3-glucuronidation and SN-38 glucuronidation with IC₅₀* of 6.01 μM and 4.31 μM, respectively, and binds to UGT1A1 with K_i of 3.55 μM. 1,2,3,6-Tetragalloylglucose also induces tumor cell apoptosis, inhibit cell proliferation, activates caspase-3 and induces DNA fragmentation in HL-60 cells. 1,2,3,6-Tetragalloylglucose also inhibits HIV integrase and reverse transcriptase, and inhibits HCV protease .

HY-N0762

Isobavachin 5 Publications Verification	Structural Classification Flavonoids Neurological Disease Classification of Application Fields Leguminosae Flavonones Phenols Polyphenols Psoralea corylifolia L. Plants Disease Research Fields Source Classification	Cytochrome P450 UGT p38 MAPK NF-κB NO Synthase COX Fc Receptor (FcR) RANKL/RANK Keap1-Nrf2 Reactive Oxygen Species (ROS) Apoptosis Autophagy
Isobavachin is an orally active, blood-brain barrier-penetrating prenylated flavonoid present in Psoralea corylifolia. Isobavachin inhibits human CYP2B6, CYP2C9, CYP2C19, *UGT1A1, UGT1A9*, and UGT2B7. Isobavachin suppresses MAPK activation, NF-κB nuclear translocation, overexpression of iNOS/COX-2, FcεRI-mediated signaling pathways, and RANKL-induced osteoclastogenesis. Isobavachin induces autophagy, cytotoxicity, neuronal differentiation, and NRF2 activation; it alleviates oxidative damage, inflammatory responses, apoptosis, iron accumulation, mitochondrial biogenesis, and mast cell degranulation. Isobavachin is applicable to research related to liver injury, inflammatory diseases, osteoporosis, liver cancer, prostate cancer, glioma, periodontitis-induced bone loss, and Alzheimer's disease .

HY-N4267

Yangambin	Cardiovascular Disease Structural Classification other families Classification of Application Fields Lignans Phenylpropanoids Plants Disease Research Fields Source Classification	Calcium Channel Platelet-activating Factor Receptor (PAFR) UGT Leukotriene Receptor TNF Receptor PGE synthase Interleukin Related
Yangambin is a PAF receptor antagonist and *UGT1A1/UGT1A3* inhibitor, with an IC₅₀ of 29.7 μM and a K_i of 17.1 μM against human *UGT1A1, and an IC₅₀* of 56.5 μM and a K_i of 66.8 μM against human UGT1A3. Yangambin blocks PAF-mediated responses, inhibits LTB₄-mediated neutrophil infiltration, and suppresses inflammatory events and anaphylactic contraction. Yangambin acts as a central nervous system inhibitor to reduce spontaneous activity, and also exhibits analgesic, anticonvulsant, antileishmanial, vasodilatory and hypotensive effects. Yangambin blocks voltage-gated Ca ²⁺ channels, reduces the production of NO, TNF-α, IL-6 and PGE2 in cells, increases the production of IL-10, and exerts a protective effect against cardiovascular injury. Yangambin can be used in research related to allergies, cutaneous leishmaniasis, central nervous system diseases and cardiovascular diseases .

HY-N1902R

4-Hydroxyphenylacetic acid (Standard)	Structural Classification Human Gut Microbiota Metabolites Monophenols Phenols Plants Compositae Endogenous metabolite Erythrina latissima E. Mey. Source Classification	Reference Standards Keap1-Nrf2 Endogenous Metabolite
4-Hydroxyphenylacetic acid (Standard) is the analytical standard of 4-Hydroxyphenylacetic acid. This product is intended for research and analytical applications. 4-hydroxyphenylacetic acid, a major microbiota-derived metabolite of polyphenols, is involved in the antioxidative action. 4-hydroxyphenylacetic acid induces expression of Nrf2 . IC₅₀ & Target:Nrf2 In Vivo: 4-Hydroxyphenylacetic acid (6, 12, or 25 mg/kg) increases Nrf2 translocation to the nucleus and enhances the activity of phase II and antioxidant enzymes. The protein levels of nuclear Nrf2 are increased by 170% and 230% in pre-treated 12 and 25 mg/kg 4-Hydroxyphenylacetic acid groups, respectively, compared with the control group.The 4-Hydroxyphenylacetic acid pretreatment at a final dose of 25 mg/kg markedly and selectively up-regulated the target genes of phase II enzymes and resulted in higher up-regulation than that of the control group by 270%, 400%, and 500% or UGT1A1, UGT1A9, and SULT2A1, respectively. 4-Hydroxyphenylacetic acid also suppresses the expression of CYP2E1 .

온라인 문의

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
호칭			Country or Region *
고객명 *			회사명 *
Department *
메일주소 *			상품명 *
Cat. No.			Requested quantity *
전화번호 *
비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

Name
이메일 *

	Sorry, but the email address you supplied was invalid.

UGT1A1-IN-1

Inhibitors & Agonists

NaturalProducts

Natural
Products